calling biotech, page-6

Biotech, you may not be in position to answer this but Ill ask anyway...

why hasn't your company decided to purchase ADO's products if they can achieve a 30%+ cost saving on the plates?

Is it because change in supplier (or change generally) is slow in the medical arena?

I believe in the disruptive story of ADO and it is a potential game changer for pathology labs and beyond.

The unknown I guess is the pace of change (and therefore revenue streams from direct product selling and royalties from large third party contracts)

Its all a waiting game. but my bet is it will just take a couple of large companies to make the change to mix n go and small and medium companies will follow.

Exciting times for ADO (and shareholders)

Maddoc